Compare
Up to four compounds, side by side.
Useful for choosing between similar peptides or planning a stack.
Add a peptide
| Attribute | GLP-1 / GIP Dual Agonist Tirzepatide |
|---|---|
| Summary | Dual-agonist successor to semaglutide — larger average weight loss in trials. |
| Mechanism | Dual GLP-1 + GIP receptor agonist. Produces deeper appetite suppression and metabolic improvements than GLP-1 alone. |
| Top outcomes |
|
| Evidence | established |
| Half-life | ~5 days |
| Administration | subq |
| Legal status | rx only |
| Safety | GI side effects common. Same MTC warning as semaglutide. |